3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Renal Cell
17
Gastrointestinal Stromal Tumors
10
Neoplasms
5
Neoplasm Metastasis
4
Multiple Myeloma
4
Kidney Neoplasms
4
Urologic Neoplasms
2
Thyroid Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Meningioma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Kidney Diseases
2
Gastrointestinal Neoplasms
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Adenoma, Islet Cell
2
Uveal Melanoma
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Rectal Neoplasms
1
Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Interventions
Dexamethasone
17
Lenalidomide
15
Bortezomib
12
Cyclophosphamide
7
fludarabine
6
carfilzomib
6
Melphalan
6
daratumumab
5
Calcium Dobesilate
5
pomalidomide
3
gamma-Globulins
3
fludarabine phosphate
3
belantamab mafodotin
3
Whole-Body Irradiation
3
Trimethoprim, Sulfamethoxazole Drug Combination
3
Tacrolimus
3
Mycophenolic Acid
3
isatuximab
2
elotuzumab
2
Sirolimus
2
Prednisone
2
Immunoglobulins, Intravenous
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
Ciprofloxacin
2
Amoxicillin-Potassium Clavulanate Combination
2
venetoclax
1
thymoglobulin
1
siltuximab
1
poly ICLC
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasms, Plasma Cell
×
Sunitinib
×
1 year
×
Clear all
No trials found.